Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Cybin inc save search
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 0.65%
H: 3.49%
C: 3.49%
first fibromyalgia treatment trial therapeutics
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
Published: 2023-10-03 (Crawled : 12:30) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 1.75%
H: 0.43%
C: -7.03%
cyb003 treatment study phase 2
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
Published: 2023-01-05 (Crawled : 12:20) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 5.26%
H: 8.21%
C: 3.15%
treatment trial therapeutics psilocybin
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-08-30 (Crawled : 12:20) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: -1.89%
H: 4.81%
C: 4.81%
cyb003 treatment trial phase 1 major depressive disorder
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-07-12 (Crawled : 13:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: -0.69%
H: 0.87%
C: -0.3%
cyb003 treatment drug trial corporation phase 1 major depressive disorder
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 0.44%
H: 8.47%
C: 4.24%
cyb003 treatment fda clearance trial potential phase 1 major depressive disorder
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-06-09 (Crawled : 22:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 2.23%
H: 0.51%
C: -10.52%
cyb003 treatment trial approval review phase 1 major depressive disorder
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-05-31 (Crawled : 13:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 6.13%
H: 3.93%
C: 0.0%
cyb003 treatment fda application trial phase 1 major depressive disorder
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-04-21 (Crawled : 13:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: -1.7%
H: 0.0%
C: 0.0%
cyb003 treatment drug trial corporation phase 1 major depressive disorder
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
Published: 2022-02-09 (Crawled : 13:30) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 2.8%
H: 0.0%
C: 0.0%
cyb004 treatment order patent grant
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
Published: 2021-12-15 (Crawled : 13:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: -0.88%
H: 9.82%
C: 9.82%
cyb004 treatment ema order patent
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
Published: 2021-12-08 (Crawled : 13:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: -1.54%
H: 3.91%
C: -0.78%
alcohol use disorder treatment order thc major depressive disorder
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
Published: 2021-11-23 (Crawled : 13:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 0.65%
H: 0.0%
C: -5.16%
treatment granted grant
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
Published: 2021-11-08 (Crawled : 14:00) - biospace.com/
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 1.73%
H: 0.0%
C: -14.89%
treatment positive psilocybin
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
Published: 2021-10-11 (Crawled : 13:00) - prnewswire.com
KTTA | $7.15 -1.19% 540
|
|
| O: 0.76%
H: 5.3%
C: -0.76%
CYBN | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 0.48%
H: 1.9%
C: 1.42%
ATAI | $1.85 -3.14% -3.24% 940K
|
Manufacturing
|
| O: -4.4%
H: 2.22%
C: -0.16%
CMPS | $8.35 -0.83% -0.84% 370K
|
Health Technology
|
| O: 2.06%
H: 2.83%
C: 1.01%
treatment drug
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.